文献速递淋巴瘤

阿维鲁单抗治疗复发或难治性结外NK/T细胞淋巴瘤:一项开放标签2期研究

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
PubMed 文献 · Blood · 2020-01-01

这项开放标签2期研究评估了抗PD-L1抗体阿维鲁单抗治疗复发或难治性结外NK/T细胞淋巴瘤的疗效与安全性,21例患者接受10 mg/kg阿维鲁单抗治疗。完全缓解率为24%(5/21),总缓解率为38%(8/21),疗效与肿瘤组织PD-L1表达显著相关(P = .001)。

要点

  • 阿维鲁单抗单药在部分复发或难治性ENKTL患者中显示活性,完全缓解率24%(5/21),总缓解率38%(8/21)。
  • 缓解与肿瘤组织PD-L1表达显著相关(P = .001),所有达完全缓解者均显示高PD-L1表达。
  • 多数治疗相关不良事件为1或2级,未观察到4级不良事件。

核心结论

  • 阿维鲁单抗在部分复发或难治性结外NK/T细胞淋巴瘤患者中显示出单药活性。
  • 评估肿瘤细胞PD-L1表达可能有助于识别阿维鲁单抗的缓解者。

研究设计与样本

  • 开放标签2期研究,纳入21例复发或难治性结外NK/T细胞淋巴瘤患者。
  • 阿维鲁单抗10 mg/kg于28天周期的第1天和第15天给药。
  • 主要终点为基于最佳缓解的完全缓解率。
  • 对治疗前肿瘤组织进行靶向测序和免疫组化,治疗前后采血检测细胞因子及可溶性PD1、PD-L1和PD-L2。

主要发现

  • 完全缓解率为24%(5/21),总缓解率为38%(8/21)。
  • 无缓解者出现早期进展,5例缓解者目前继续接受治疗并维持缓解。
  • 多数治疗相关不良事件为1或2级,未观察到4级不良事件。
  • 治疗缓解与突变谱、肿瘤突变负荷、血清细胞因子水平及可溶性PD1/PD-L1和PD-L2均无相关性。
  • 阿维鲁单抗的缓解与肿瘤组织PD-L1表达显著相关(P = .001),所有达完全缓解者均显示高PD-L1表达,基于PD-L1表达的肿瘤分型与治疗缓解相关。

关键数值与推荐

  • 完全缓解率24%(5/21),总缓解率38%(8/21)。
  • 缓解与肿瘤组织PD-L1表达显著相关(P = .001)。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to assess the efficacy and safety of treatment with avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL). In this phase 2 trial, 21 patients with relapsed or refractory ENKTL were treated with 10 mg/kg of avelumab on days 1 and 15 of a 28-day cycle. The primary end point was the complete response (CR) rate based on the best response. Targeted sequencing and immunohistochemistry were performed using pretreatment tumor tissue, and blood samples were drawn before and after treatment for measurement of cytokines and soluble programmed cell death protein 1 (PD1), PD-L1, and PD-L2. The CR rate was 24% (5 of 21), and the overall response rate was 38% (8 of 21). Although nonresponders showed early progression, 5 responders currently continue to receive treatment and have maintained their response. Most treatment-related adverse events were grade 1 or 2; no grade 4 adverse events were observed. Treatment responses did not correlate with mutation profiles, tumor mutation burden, serum levels of cytokines, or soluble PD1/PD-L1 and PD-L2. However, the response to avelumab was significantly associated with the expression of PD-L1 by tumor tissue (P = .001). Therefore, all patients achieving CR showed high PD-L1 expression, and their tumor subtyping based on PD-L1 expression correlated with treatment response. In summary, avelumab showed single-agent activity in a subset of patients with relapsed or refractory ENKTL. The assessment of PD-L1 expression on tumor cells might be helpful for identifying responders to avelumab. This trial was registered at www.clinicaltrials.gov as #NCT03439501.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Blood. 2020. PMID: 32766875. doi:10.1182/blood.2020007247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。